An alarming number of Hepatitis C patients in Russia is driving the country’s pharmaceutical industry, with Roche and Schering-Plough benefitting particularly.

According to the ‘Russian Pharma Sector Forecast to 2013’ report compiled by industry intelligence firm RNCOS , augmented use of intravenous drugs and high-risk sexual activities, combined with an unhygienic lifestyle, have caused the disease to steadily increase in Russia.

The report indicates that the market would grow at a CAGR of 9% during the 2009-2013 period, with Roche’s Pegasys and Schering-Plough’s PegIntron medications benefitting from the increase.

The report also revealed that the growth of the sector is being driven by support from the government for related medications, as well as increasing private investments.